Gubra

Prenumeration

Kalender

	Est. tid*
2026-02-27	N/A	Bokslutskommuniké 2025
2025-08-21	07:30	Kvartalsrapport 2025-Q2
2025-04-04	N/A	X-dag ordinarie utdelning GUBRA 0.00 DKK
2025-04-03	N/A	Årsstämma
2025-02-28	-	Bokslutskommuniké 2024
2024-08-23	-	Kvartalsrapport 2024-Q2
2024-04-04	-	X-dag ordinarie utdelning GUBRA 0.00 DKK
2024-04-03	-	Årsstämma
2024-02-28	-	Bokslutskommuniké 2023
2023-11-01	-	Extra Bolagsstämma 2023
2023-08-25	-	Kvartalsrapport 2023-Q2

Beskrivning

Land	Danmark
Lista	Mid Cap Copenhagen
Sektor	Hälsovård
Industri	Medicinteknik

Gubra är ett läkemedelsbolag. Bolagets verksamhet är fokuserad på de tidiga stadierna av läkemedelsutveckling. De driver huvudsakligen forskning och utveckling inom området för metabola och fibrotiska sjukdomar.. Bolagets produktportfölj innefattar ett flertal varumärken och läkemedel, och verksamheten bedrivs på global nivå, med störst närvaro inom Nordamerika och Norden. Huvudkontoret ligger i Hørsholm, Danmark.

Filter

År

Typ

Språk

Rensa

2025-03-10 12:57:00 NOTICE TO CONVENE ANNUAL GENERAL MEETING 2025 465,00 DKK | -9,18% | 55,5 MDKK

2025-03-03 07:08:00 AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity 650,00 DKK | +15,25% | 198 MDKK

2025-02-28 07:30:00 Annual Report 2024: Excellent performance across Gubra 564,00 DKK | -12,42% | 187 MDKK

2025-01-15 07:30:00 Gubra appoints new Chief Operating Officer 670,00 DKK | +0,90% | 7,93 MDKK

2024-12-30 13:30:00 Gubra Announces New Collaboration with Amylyx Pharmaceuticals to Develop a Novel Long-acting GLP-1 Receptor Antagonist 624,00 DKK | -0,95% | 29,4 MDKK

2024-11-13 18:36:00 Gubra announces positive GUBamy Phase 1 SAD data (correction) 686,00 DKK | +43,51% | 224 MDKK

2024-11-13 17:41:00 Gubra announces positive GUBamy Phase 1 SAD data 686,00 DKK | +43,51% | 224 MDKK

2024-11-07 07:30:00 Trading statement Q3-2024: Another strong quarter 425,00 DKK | -1,39% | 19,6 MDKK

2024-10-31 11:07:00 Gubra announces discontinuation of development of NYP2 in obesity with Boehringer Ingelheim 430,00 DKK | -4,02% | 69,2 MDKK

2024-09-06 21:42:00 Major shareholder announcement

2024-08-22 07:30:00 Interim report H1 2024: Strong performance across Gubra 620,00 DKK | +1,31% | 78,0 MDKK

2024-08-21 17:12:00 Gubra raises financial outlook for 2024 620,00 DKK | +1,31% | 78,0 MDKK

2024-07-10 23:38:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 628,00 DKK | +14,18% | 140 MDKK

2024-07-02 20:25:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 590,00 DKK | +4,24% | 52,7 MDKK

2024-07-01 07:30:00 Boehringer Ingelheim and Gubra announce start of clinical development of a potential first-in-class, triple agonist, obesity treatment 602,00 DKK | +23,11% | 119 MDKK

2024-06-28 12:05:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 489,00 DKK | +6,30% | 35,7 MDKK

2024-06-04 15:30:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 326,00 DKK | -0,61% | 6,72 MDKK

2024-06-04 15:25:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 326,00 DKK | -0,61% | 6,72 MDKK

2024-05-07 07:30:00 Trading statement Q1-2024: Strong start to the year 348,00 DKK | +12,62% | 66,8 MDKK

2024-05-06 17:15:00 Gubra raises financial outlook for 2024 348,00 DKK | +12,62% | 66,8 MDKK

2024-04-17 07:30:00 Gubra unveils UCN2 as novel anti-obesity drug candidate for healthy weight loss 304,00 DKK | +8,96% | 25,7 MDKK

2024-04-04 12:32:00 RESOLUTIONS OF GUBRA A/S' ANNUAL GENERAL MEETING 2024 299,00 DKK | +0,67% | 12,9 MDKK

2024-04-03 21:45:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 299,00 DKK | +0,67% | 12,9 MDKK

2024-04-03 21:35:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 299,00 DKK | +0,67% | 12,9 MDKK

2024-03-27 14:45:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 291,00 DKK | +11,92% | 35,8 MDKK

2024-03-26 22:45:00 Major shareholder announcement: The Capital Group Companies Inc. 291,00 DKK | +11,92% | 35,8 MDKK

2024-03-25 11:29:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 281,00 DKK | -6,33% | 182 MDKK

2024-03-25 09:56:00 Major shareholder announcement 281,00 DKK | -6,33% | 182 MDKK

2024-03-06 09:00:00 NOTICE TO CONVENE ANNUAL GENERAL MEETING 2024 221,00 DKK | +0,45% | 12,1 MDKK

2024-03-04 21:41:00 Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 220,00 DKK | +4,76% | 22,6 MDKK

2024-02-28 07:30:00 Annual Report 2023 – Revenue in the CRO business growing by 29% to record high level 185,00 DKK | +8,82% | 7,37 MDKK

2024-01-26 13:33:00 Gubra concludes the research agreement with UK Biotech 121,00 DKK | -0,82% | 0,10 MDKK

2023-12-13 17:19:00 Gubra and Boehringer Ingelheim sign 4th partnership, expanding their successful obesity treatment discovery collaboration 124,00 DKK | +4,84% | 7,09 MDKK

2023-11-29 12:51:00 Gubra announces first subject dosed in Phase 1 clinical trial of amylin agonist (GUBamy) for the treatment of obesity 117,04 DKK | +2,11% | 0,01 MDKK

2023-11-08 07:30:00 Trading statement Q3-2023: Continued strong performance 113,00 DKK | -0,62% | 0,46 MDKK

2023-11-01 11:01:00 Gubra strengthens Board of Directors 109,98 DKK | -0,02% | 0,07 MDKK

2023-11-01 10:40:00 Gubra - Extraordinary general meeting 109,98 DKK | -0,02% | 0,07 MDKK

2023-10-26 12:35:00 Gubra enters into a Market Maker Agreement 100,98 DKK | +7,19% | 0,24 MDKK

2023-10-26 08:01:00 Gubra raises financial guidance for full-year 2023 100,98 DKK | +7,19% | 0,24 MDKK

2023-10-24 07:30:00 Gubra opens its first US office in Boston 94,20 DKK | -0,89% | 0,04 MDKK

2023-10-09 14:00:00 NOTICE TO CONVENE EXTRAORDINARY GENERAL MEETING 104,02 DKK | -0,04% | 0,01 MDKK

2023-09-06 09:58:00 Gubra submits clinical trial application (CTA) for first-in-human amylin trial 116,60 DKK | +4,82% | 1,06 MDKK

2023-09-01 11:41:00 Completion of share buy-back programme 115,00 DKK | +1,77% | 0,17 MDKK

2023-08-28 08:15:00 Gubra resumes its share buy-back programme to hedge incentive scheme obligations 107,02 DKK | -1,35% | 3,75 MDKK

2023-08-25 07:30:00 Interim report H1-2023: Strong performance and ahead of expectations 108,48 DKK | -1,83% | 0,26 MDKK

2023-08-23 16:44:00 Gubra announces termination of collaboration with Bayer 104,00 DKK | -2,80% | 13,5 MDKK

2023-08-21 15:29:00 Gubra A/S announces signing of collaboration agreement with Hemab ApS 107,98 DKK | +5,88% | 0,34 MDKK

2023-08-15 13:19:00 Gubra raises financial guidance for full-year 2023 99,35 DKK | +7,05% | 0,51 MDKK

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Gubra

Prenumeration

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden